alexa Orexinergic System Dysregulation in Depression | OMICS International
ISSN: 2378-5756
Journal of Psychiatry
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Orexinergic System Dysregulation in Depression

Sergio Chieffi*

Department of Experimental Medicine, Section of Human Physiology, Second University of Naples, Italy

*Corresponding Author:
Sergio Chieffi
Department of Experimental Medicine
Section of Human Physiology
Second University of Naples, Italy
Tel: 02044190615
E-mail: [email protected]

Received Date: December 23, 2016; Accepted Date: December 26, 2016; Published Date: January 06, 2017

Citation: Chieffi S (2016) Orexinergic System Dysregulation in Depression. J Psychiatry 20:e107 doi:10.4172/2378-5756.1000e107

Copyright: © 2016 Chieffi S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Journal of Psychiatry


Depression is an affective disorder characterized, in particular in its more severe form, i.e., major depressive disorder (MDD), by persistent symptoms of unpleasant (dysphoric) mood, inability to experience pleasure (anhedonia), and a generalized loss of interest in most or all normal activities [1]. Depression is often associated with physiological and cognitive symptoms. Physiological symptoms include sleep disorders, changes in appetite, tiredness and lack of energy; cognitive symptoms consist of trouble thinking, concentrating, remembering things, and recurrent thoughts of death and suicidal thoughts. Several brain regions regulating emotion and cognition have been implicated in depression, such as the prefrontal cortex, the cingulate cortex, the nucleus accumbens, the amygdala, the hippocampus and the hypothalamus [2]. A variety of factors seem to be involved in the pathophysiology of depression, such as the occurrence of psychosocial stressful events, changes in the function and effect of monoamines and abnormal functioning of the hypothalamic–pituitary–adrenal (HPA) axis. The activation of the HPA axis is common in depressed patients. The excessive secretion of cortisol damages mature neurons and suppresses normal neurogenesis, leading to a reduction of hippocampal volume. It is important to note that the hippocampus inhibits the hypothalamic corticotrophin releasing factor (CRH) secretion. Thus, the damage to the hippocampus may lead to a vicious cycle in which the loss of inhibitory control of CRH secretion would lead to greater cortisol release, producing additional hippocampal atrophy [3].

Recently, several experimental observations have led to propose the involvement of orexinergic system in pathophysiology of depression. The orexinergic system regulates functions that are disturbed in depressive states such as sleep, feeding behavior, and reward system and stress response. Both hypoactivity and hyperactivity of orexinergic system have been found to be associated with depression and could reflect the heterogeneity of depression [4,5]. The orexin-A (OX-A) and orexin-B (OX-B) (hypocretin-1 and hypocretin-2) are neuropeptides synthesized by a cluster of neurons in the lateral hypothalamus. Orexins selectively act on two G protein-coupled receptors: the orexin/ hypocretin 1 receptor (Ox1R/HcrtR1), which has higher affinity to OX-A, and the orexin/hypocretin 2 receptor (Ox2R/HcrtR2), which has equal affinity to both OX-A and OX-B [6,7]. Orexinergic neurons receive a variety of signals related to environmental, physiological and emotional stimuli, and project broadly to the entire CNS. Orexinergic projections are involved in regulating wakefulness and arousal, motivation and emotions, feeding behavior and motor and autonomic functions [8-14].

Salomon et al. [15] found that cerebrospinal fluid (CSF) OX-A levels in depressive subjects trended to be higher than in control, and varied less than in controls across the diurnal cycle. Surprisingly, OX-A levels were lowest at midday, although the orexin is a hypothetically wake-promoting peptide. It is probable that the orexin levels are lowest at midday since there is a long delay between OX-A release and its appearance in CSF [16]. However, others studies found a decrease of CFS OX-A levels in depression. Brundin et al. [17,18] explored the CSF level of OX-A in depressed patients admitted to hospital shortly after a suicide attempt. Brundin L et al. [17] found significant and negative correlations between CSF-orexin and two psychiatric symptoms of the Comprehensive Psychopathological Rating Scale (lassitude and slowness of movement), and the ratings of global illness, as observed by a psychiatrist. Interestingly, Brundin et al. [18] observed that orexin correlated significantly with CSF levels of CRF, suggesting that orexin and the HPA-axis hormones interact in humans. This was supported by the observation that intracerebroventricular (i.c.v.) infusion of OX-A activates CRF neurons of the paraventricular nucleus of the hypothalamus [19] and elevates HPA hormones [20]. Although the majority of studies showed an activation of the HPA-axis in depression [21], other researches reported a reduction of CRF in suicidal patients with MDD [22,23]. Brundin et al. [18] proposed that in severe and chronic depression the HPA-axis becomes exhausted and the CRH secretion reduced.

Experimental observations supporting the hypothesis of an orexinergic system dysregulation in depression were also obtained using animal models. Flinders Sensitive Line (FSL) rats [24] are considered as a genetic animal model of depression. These rats exhibit an increase of immobility in the forced swim test (FST), a commonly used measure of depressive behavior, and display characteristics similar to those of depressed patients including lower body weight, decreased appetite and reduced REM sleep latency. Importantly, FSL rats showed a higher number of orexin neurons in the hypothalamus than Flinders Resistant Line rats [24]. Negative effects related to overactivation of orexin neurons were observed by Nollet et al. [25,26]. The authors [25] exposed mice to the unpredictable chronic mild stress (UCMS), a rodent model of depression. UCMS induced orexin neurons overactivation, HPA axis dysregulation and the suppression of cell proliferation and neurogenesis in the hippocampus. Some of these effects were reversed by the administration of almorexant, a dual orexin receptor antagonist. Almorexant induced antidepressant-like effect preventing the HPA axis dysregulation, but it did not reversed the UCMS-induced hippocampal cell proliferation and neurogenesis suppression [26]. However, these observations were at odds with studies that used a different genetic animal model of depression, the Wistar-Kyoto (WKY) rats. WKY rats exhibit depressive characteristics and patterns of sleep disruption similar to that observed in depressed human patients. WKY rats had fewer (about 18%) and smaller (about 15%) OX-A neurons in the hypothalamus compared to control Wistar rats [27]. These observations [27] were in agreement with those reported by Taheri et al. [28] who found a decrease of about 22% in hypothalamic preproorexin mRNA in WKY rats. Some studies have investigated the links between orexins, depression and hippocampal neurogenesis. Arendt et al. [29] found that mice displaying more severe depressive behavior in FST had lower hippocampal expression of OX-A. Furthermore, the i.c.v. administration of OX-A led to a significant reduction in animal immobility in the FST, without changing the corticosterone blood level, and an increase in the number of cells in the dentate gyrus [30]. Ito et al. [30] suggested that the enhancement of cell proliferation in the dentate gyrus by OX-A might have an antidepressive-like effect. The treatment with the OXR1 antagonist SB-334867 blocked both the OX-A-induced decrease in the FST immobility and the increase in the number of cells in the dentate gyrus.

Experimental evidence suggest that physical exercise has beneficial effects on mood regulation and improves cognition [31,32]. These beneficial effects are associated with morphological and functional changes of brain regions involved in mood regulation and cognition such as prefrontal region [33-36] and the hippocampus [37]. Interestingly, these regions are often reported to deteriorate with aging [38] and be severely affected in Alzheimer’s disease [39,40]. The exercise-induced beneficial effects on hippocampus would depend on more factors including the enhancement of vascularisation, the upregulation of neurotrophic factors and, possibly, an increase of OX-A levels. An increase of OX-A levels with physical exercise has been reported in rats [41], dogs [42], cats [43], and humans [44].

Taken together, the studies reported suggest an involvement of orexinergic system in depressive disorders. However, the exact nature of the orexinergic dysfunction is not yet fully understood. Human and animal studies led to conflicting results, being depressive state associated with either hypoactivity or hyperactivity of the orexinergic system. However, most studies focused on a general diagnosis of depression. They did not distinguish the role of orexin system in different subtypes of depression that might depend on different pathophysiological mechanisms. Further investigations are necessary to clarify the mechanisms linking orexinergic system and depression in animals and humans.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 1354
  • [From(publication date):
    January-2017 - Jul 20, 2018]
  • Breakdown by view type
  • HTML page views : 1254
  • PDF downloads : 100

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7